Today saw the launch of Eastra Health, the world’s first female-focused biotech company dedicated to developing psychedelic-derived medicines specifically for women. Eastra Health will offer new solutions for under-addressed health conditions like menstrual pain or menopause through an innovative approach to drug discovery and a deep, holistic understanding of women’s health, biology, and specific needs. “For years, women have been overlooked by…
An estimated 5 million women in the U.S. suffer from symptoms of uterine fibroids, and an estimated 3 million women are inadequately treated by current medical therapy and require further treatment. Uterine fibroids are noncancerous tumors that develop in or on the muscular walls of the uterus and are among the most common reproductive tract tumors in women. In addition to an individual’s genetic…
Women’s Health Biotech Celmatix focused uniquely on ovarian biology has announced the appointment of Dr. Stephen Palmer as Chief Scientific Officer. Dr. Palmer had previously joined the company’s Scientific Advisory Board earlier this year, on the heels of rapid progress with Celmatix’s lead AMHR2 agonist program and the out-licensing of PCOS targets from its multi-omics ovarian health platform. Dr. Palmer is a…
BioVaxys has announced that Charles J. Dunton, MD has joined BioVaxys as an Advisor to help provide additional scientific support for BVX-0918A, the Company’s ovarian cancer vaccine candidate, and its planned marketing and sale of Papilocare in the United States. Dr. Dunton, a top global opinion leader, is a gynecologist/oncologist in Indiana. He received his medical degree from Jefferson Medical College and has been in…
Evofem today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women. Fast Track designation is designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs. According to a new report published by the Centers for Disease…
Only a month after announcing its acquisition of Alydia Health, Merck hosted spin-off Organon‘s management at a meeting with the investor community yesterday. Organon’s leadership shared plans for how the company will deliver sustainable growth and shareholder value as a standalone company. Notable is the strong intended focus on women’s health and plan for more acquisitions in this space. At launch, Organon’s…
Sera Prognostics, “The Pregnancy Company”, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the completion of a $100 million Series E financing. Several leading healthcare-focused institutional investors have joined this financing round, including Vivo Capital, aMoon Fund, Parian Global, and others, led by existing investors Anthem, Inc., and Blue Ox Healthcare…
Evofem Biosciences has announced that two new data sets from its Phase 3 AMPOWER trial evaluating Phexxi (lactic acid, citric acid, potassium bitartrate) will be presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM). The meeting will be conducted virtually from April 30 – May 2, 2021. “These new data sets provide clinical insights into how women used Phexxi…
